NCT01632358View on ClinicalTrials.gov

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Dyslipidaemia
Interventions
DRUG

TAP311 capsules

DRUG

Placebo

Trial Locations (3)

11941

Novartis Investigative Site, Amman

33025

Novartis Investigative Site, Miramar

40447

Novartis Investigative Site, Taichung

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY